Johnson & Johnson: to buy drug delivery technology firm
(CercleFinance.com) - Johnson & Johnson will buy Taris Biomedical, a US biotechnology company specializing in the development of a novel drug delivery system, as the diversified healthcare giant pushes into the market for medical technologies.
The privately-owned company's lead clinical-stage product, TAR-200, features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder for the treatment of diseases such as cancer.
Financial terms of the deal were not disclosed.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The privately-owned company's lead clinical-stage product, TAR-200, features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder for the treatment of diseases such as cancer.
Financial terms of the deal were not disclosed.
Copyright (c) 2019 CercleFinance.com. All rights reserved.